Therapeutic vaccination against active Tuberculosis
AssigneeCrucell Holland B.V.
InventorsJerald Sadoff, Anisah Alyahya
Life of this patent
Estimating the term…
Abstract
The invention provides a method for therapeutic treatment of a patient having active tuberculosis (TB), the method comprising: administering to the patient a recombinant adenovirus vector that comprises nucleic acid encoding the Ag85A, Ag85B and TB10.4 antigens of Mycobactium tuberculosis (Mtb). Advantageously, the method can be used to shorten conventional drug therapy for treating active TB.
Claims10
A method of treating a patient having active tuberculosis (TB), the method comprising:
- administering to the patient a recombinant adenovirus vector comprising nucleic acid encoding Ag85A, Ag85B, and TB10.4 antigens of Mycobacterium tuberculosis, and
- treating the patient further with drug therapy for tuberculosis, wherein the drug therapy comprises:
- administration of isoniazid, rifampin, pyrazinamide, and ethambutol to the patient.
A method of treating a patient having active tuberculosis (TB), the method comprising:
- administering to the patient a recombinant adenovirus vector comprising nucleic acid encoding Ag85A, Ag85B, and TB10.4 antigens of Mycobacterium tuberculosis (Mtb), and
- treating the patient further with drug therapy for tuberculosis, wherein the bacterial burden of Mtb as measured in a group of patients at a given time after the initiation of drug therapy is lower as compared to the burden at the same time point without the administration of said recombinant adenovirus vector.
A method of treating a patient having active tuberculosis, the method comprising:
- administering to the patient a recombinant adenovirus vector comprising nucleic acid encoding Ag85A, Ag85B, and TB10.4 antigens of Mycobacterium tuberculosis, wherein the recombinant adenovirus vector is a replication-deficient human adenovirus of serotype 26.
A method of treating a patient having active tuberculosis (TB), the method comprising:
- administering to the patient a recombinant adenovirus vector comprising nucleic acid encoding Ag85A, Ag85B, and TB10.4 antigens of Mycobacterium tuberculosis (Mtb), wherein the recombinant adenovirus vector is administered in a heterologous prime-boost regimen.
A method of treating a patient having active tuberculosis (TB), the method comprising:
- administering to the patient a recombinant adenovirus vector comprising nucleic acid encoding Ag85A, Ag85B, and TB10.4 antigens of Mycobacterium tuberculosis (Mtb), wherein the TB is pulmonary TB.
A method of treating a patient having active tuberculosis (TB), the method comprising:
- administering to the patient a recombinant adenovirus vector comprising nucleic acid encoding Ag85A, Ag85B, and TB10.4 antigens of Mycobacterium tuberculosis (Mtb), wherein the patient has an infection with multidrug-resistant Mtb (MDR-TB) or extremely drug-resistant Mtb (XDR-TB).
A method of treating a patient having active tuberculosis, the method comprising:
- administering to the patient a recombinant adenovirus vector comprising nucleic acid encoding Ag85A, Ag85B, and TB10.4 antigens of Mycobacterium tuberculosis (Mtb), wherein the recombinant adenovirus vector comprising nucleic acid encoding Ag85A, Ag85B, and TB10.4 antigens of Mtb is administered to the patient more than once.
Dependencies are inferred from the claim text.